Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Legal Project Management

Knowledge Management

Legal Technology Services

Patent Litigation

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Chancery & Corporate Governance

<p><em>Inter Partes </em>Review</p>

Post-Grant Review

<p><em>Ex Parte</em> Reexamination</p>

Supplemental Examination

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Electrical & Computer Technology

Software & Internet

Consumer Electronics

Artificial Intelligence

Digital Media & E-Commerce

Financial, Business & FinTech Services

Telecommunications

Energy & Chemicals

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Autonomous Vehicles

Thought Leadership

IP Law Essentials

Post-Grant Annual Reports

Janis K. Fraser, Ph.D.

Title
Principal: Offices
Boston: Phone Numbers
617-521-7037: Email
[email protected]

Insights

Academic courses

Co-creator and lecturer for Patent Resources Group Advanced Patent Law Course, “Pharma & Biotech Patents: A Hatch-Waxman and BPCIA (Biosimilars) Immersion Course Encompassing Prosecution Strategies, FDA Regulation, Post-Grant Challenge, and Litigation” (2015-2019)
Co-creator and lecturer for Patent Resources Group Advanced Patent Law Course, “Pharma & Biotech Strategies for Patent Prosecution, Hatch-Waxman, and Litigation” (2000-2014)

Additional insights

Publications

“Patent-eligible Subject Matter in the Life Sciences in the United States,” Japanese IP Journal, Vol. 16 No. 1: 20-30 (2019)
“An End-Run Around Myriad And ‘Product Of Nature’ Problem,” Law360 (September 2016)
“Bulletproofing Pharma Patents,” LSIPR Newsletter (December 2014)
“Patenting Genes in a Post-Myriad World,” Industrial Biotechnology (August 2013)

“Myriad: Picking Up the Pieces,” LSIPR Newsletter (June 2013).
“Making Follow-On Biologics a Reality,” Genetic Engineering & Biotechnology News 31:8-10 (2011)
“U.S. Gene Patents in Legal Limbo—for Now,” Genetic Engineering & Biotechnology News 28:10 (2008)
“In Vitro HeLa DNA Synthesis: Investigation of the Nature of Replication and a Stimulatory Factor from HeLa Cells,” Ph.D. Thesis